by Alex Kadhim
Researchers at Beth Israel Deaconess Medical Center and collaborators have found thatdurable remission following CART-cell therapy (axicabtagene ciloleucel;Axi-cel) inpatients with...
by Alex Kadhim
Researchers at the University Hospital of Erlangen, Germany, have found that alloreactive donor T-cells upregulate the immune checkpoint molecule CD47 following allogeneic hematopoietic cell...
by Cancer Immunology, Immunotherapy
Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM).
by Blood Advances
Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.
by Blood Advances
Chimeric antigen receptor (CAR) T-cell treatments have suboptimal performance in the setting of chronic lymphocytic leukemia (CLL), but researchers have identified a potential pathway to increase...
by Alex Kadhim
In a multicenter retrospective study published in Blood Advances, authors from multiple institutions examined the impact of prior inotuzumab ozogamicin (InO) exposure on the outcomes of...